Valuation: Adial Pharmaceuticals, Inc.

Market Cap 13.26M 11.9M 11M 9.96M 18.61M 1.26B 18.84M 132M 52.38M 661M 49.76M 48.71M 2.1B P/E 2026 *
-3.34x
P/E 2027 * -8.28x
Enterprise Value 13.26M 11.9M 11M 9.96M 18.61M 1.26B 18.84M 132M 52.38M 661M 49.76M 48.71M 2.1B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
92.92%
Yield 2026 *
-
Yield 2027 * -
1 day+36.12%
1 week+22.87%
Current month+25.94%
1 month+25.00%
3 months+71.19%
6 months+223.72%
Current year-8.18%
1 week 3.59
Extreme 3.59
5.15
1 month 3
Extreme 3
5.15
Current year 1.31
Extreme 1.31
7.2
1 year 1.31
Extreme 1.31
9.22
3 years 1.31
Extreme 1.31
104.25
5 years 1.31
Extreme 1.31
2,200
10 years 1.31
Extreme 1.31
5,900
Manager TitleAgeSince
Chief Executive Officer 42 28/10/2026
Director of Finance/CFO 47 28/10/2026
Chief Tech/Sci/R&D Officer - 16/10/2026
Director TitleAgeSince
Director/Board Member 76 01/02/2015
Director/Board Member 46 01/09/2014
Chairman 57 18/08/2022
Date Insider Type Main position Quantity % Market Cap. Importance
9/17/26 A Free

Director

25,666 0.9774%
4/7/26 A Free

Chief Financial Officer

17,325 1.2133%
4/7/26 A Free

Chairman

9,185 0.6432%
Change 5-day change 1-year change 3-year change Capi.($)
+36.12%+22.87%-46.48%-90.05% 13.26M
+0.65%-3.36%+36.98%+60.50% 64.14B
+0.70%+2.45%+12.00%+83.49% 55.53B
+0.75%+1.08%+12.27%+103.85% 53.03B
+2.76%+0.87%+27.92%+55.07% 45.99B
+2.00%-3.39%+17.83%+119.04% 42.45B
+1.34%-2.86%+224.43%+914.08% 40.45B
+0.64%-3.95%+11.15%+45.57% 32.25B
-2.21%+42.92%+104.03%+90.51% 34.47B
-2.72%-0.44%+23.18%-10.77% 24.23B
Average +4.02%+5.96%+42.33%+137.13% 39.26B
Weighted average by Cap. +0.70%+3.49%+49.20%+160.26%

Financials

2026 *2027 *
Net sales - -
Net income -65.46M -58.73M -54.3M -49.18M -91.88M -6.23B -92.99M -649M -259M -3.26B -246M -240M -10.36B -21.14M -18.96M -17.53M -15.88M -29.67M -2.01B -30.03M -210M -83.5M -1.05B -79.32M -77.65M -3.34B
Net Debt - -
Projected Income Statement - Annual - Adial Pharmaceuticals, Inc.
Logo Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc. is a biopharmaceutical company. Its lead program is AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure in development for ulcerative colitis. AT177 is a fully synthetic, patented, oral AhR agonist designed to restore mucosal immune homeostasis at the site of disease with minimal systemic exposure. AT177's active ingredient is a prodrug of indirubin, a potent AhR agonist within indigo naturalis, a botanical extract with clinical efficacy in ulcerative colitis. AT177's colon-targeted formulation delivers therapeutic AhR engagement directly to the colonic mucosa with exquisite gut restriction, minimizing the systemic AhR exposure associated with adverse effects. Its historical investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder in heavy drinking patients.
Employees
5
Date Price Change Volume
28/10/26 $5.050 +36.12% 99,654
27/10/26 $3.710 +0.82% 7,357
26/10/26 $3.680 -6.12% 11,696
23/10/26 $3.920 -7.11% 47,359
22/10/26 $4.220 +2.68% 2,269
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Adial Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.050USD
Average target price
8.333USD
Spread / Average Target
+65.02%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Adial Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ADIL Stock